Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11006533 | 0.85 | LMNA (0.43) | LMNAHTTSMN1; SMN2GAACYP17A1 | |
| SCHEMBL1226388 | 0.82 | LMNA (0.57) | LMNAHTTSMN1; SMN2GAACYP17A1 | |
| SCHEMBL30634131 | 0.82 | MMP9 (0.43) | LMNAHTTSMN1; SMN2GAACYP17A1 | |
| SCHEMBL14889652 | 0.81 | CYP2C19 (0.40) | LMNAHTTSMN1; SMN2GAACYP17A1 | |
| SCHEMBL27318062 | 0.81 | LMNA (0.51) | LMNAHTTSMN1; SMN2GAACYP17A1 | |
| SCHEMBL5670246 | 0.81 | LMNA (0.51) | LMNAHTTSMN1; SMN2GAACYP17A1 | |
| Fenbutyramide SCHEMBL1478462 | 0.80 | EPHX1 (0.63) | LMNAHTTSMN1; SMN2GAAEPHX1 | |
| Fenbutyramide SCHEMBL1477997 | 0.80 | EPHX1 (0.63) | LMNAHTTSMN1; SMN2GAAEPHX1 | |
| Fenbutyramide SCHEMBL232920 | 0.80 | EPHX1 (0.63) | LMNAHTTSMN1; SMN2GAAEPHX1 | |
| SCHEMBL18248573 | 0.80 | MMP9 (0.47) | LMNAHTTSMN1; SMN2GAACYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113087654-B | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| CN-113087654-A | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2021-07-09 | — | — | CN | claimed |
| WO-2024008196-A1 | CLASS OF AMIDE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 中国科学院上海药物研究所 | 2024-01-11 | — | — | WO | disclosed |
| CN-113087654-B | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-113087654-B | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-113087654-A | Preparation method of piperidine-4-butylamine | 苏州昊帆生物股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| CN-106660954-A | Substituted azaspiro(4.5)decane derivatives | 格吕伦塔尔有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-09-22 | — | — | US | disclosed |
| CN-1324012-C | TNF-alpha prodn. inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2007-07-04 | — | — | CN | disclosed |
| CN-1307159-C | TNF-alpha prodn. inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2007-03-28 | — | — | CN | disclosed |
| CN-1284771-C | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2006-11-15 | — | — | CN | disclosed |
| EP-1626725-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | Synta Pharmaceuticals Corporation (US) | 2006-02-22 | — | — | EP | disclosed |
| CN-1590374-A | TNF-alpha prodn. inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-03-09 | — | — | CN | disclosed |
| CN-1590375-A | TNF-alpha prodn. inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-03-09 | — | — | CN | disclosed |
| WO-2005000404-A2 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-01-06 | — | — | WO | disclosed |
| CN-1432000-A | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2003-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230428-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | LMNA 3449/4885HTT 26/4885SMN1; SMN2 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.